Bristol Myers Squibb is striking a $15 billion drug licensing deal with China's Hengrui Pharma
Culture Index
Score Breakdown
Relevance
3/25
Freshness
25/25
Authority
18/20
Brand Signal
10/15
Depth
2/15
5-Axis Cultural Radar
The agreement covers 13 early-stage programs in oncology, hematology, and immunology, with $600 million due upfront
